

DOCKET NO: ISPH-0587

SERIAL NO: 09/915,814

Response to Office Action Dated: November 17, 2004

AMENDMENT TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

Listing of claims:

1. (Currently amended) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3), wherein said compound specifically hybridizes with nucleotides 1 through 970 ~~or 1143 through 3775~~ of said nucleic acid molecule and inhibits the expression of human hormone-sensitive lipase by at least 5% in 80% confluent HepG2 cells in culture at an optimal compound concentration.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Canceled)
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

DOCKET NO: ISPH-0587

SERIAL NO: 09/915,814

Response to Office Action Dated: November 17, 2004

11. (Currently amended) A compound of 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on nucleotides 1 through 970 of a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3).

12. (Previously presented) A composition comprising the compound of claim 1 or claim 76 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (Previously presented) A method of inhibiting the expression of hormone-sensitive lipase in cells or tissues comprising contacting said cells or tissues with an amount of the compound of claim 1 or claim 76 sufficient to inhibit expression of hormone-sensitive lipase.

16-75. (Canceled)

76. (Currently amended) An oligonucleotide mimetic compound 8 to 50 nucleobases in length targeted to nucleobases 1 through 970 of a nucleic acid molecule encoding human hormone-sensitive lipase (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of the nucleic acid molecule encoding human hormone-sensitive lipase.

77. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified internucleoside linkage.

78. (Previously presented) The compound of claim 77 wherein the modified internucleoside linkage is a phosphorothioate linkage.

79. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified sugar moiety.

DOCKET No: ISPH-0587

SERIAL No: 09/915,814

Response to Office Action Dated: November 17, 2004

80. (Previously presented) The compound of claim 79 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

81. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound comprises at least one modified nucleobase.

82. (Previously presented) The compound of claim 81, wherein the modified nucleobase is a 5-methylcytosine.

83. (Previously presented) The compound of claim 76 wherein the oligonucleotide mimetic compound is a chimeric oligonucleotide.